Last Rebalance

RELX PLC (REL.L) · DECREASE · Net Flow +£2,845.55

Analysis: RELX holds premium valuation supported by high ROIC, recurring subscription revenues (~80%+), and strong earnings quality with consistent upgrades. Recent results showed resilient growth; momentum recovering post-AI disruption fears. Balance sheet resilient with low net debt and excellent liquidity (high avg daily volume). AI thesis durable: structured data/analytics critical for AI training, inference, and enterprise tools; partnerships and product integrations (e.g. legal/scientific AI) position for net positive impact.

Bull Case: AI-driven demand for high-quality structured data and analytics accelerates RELX revenue growth to 8-10%+ CAGR with margin expansion as AI features command premium pricing over 6-18 months.

Bear Case: Generative AI disrupts traditional content aggregation and search workflows, pressuring pricing power or causing faster-than-expected substitution in key verticals (legal, scientific).

Reason: Trim from 29% to alleviate excessive concentration risk while retaining core exposure to AI data/analytics leader; analysts highlight limited displacement risk and net positive data-consumption tailwinds from AI platforms.

Key Risk: AI platform substitution eroding RELX's data moat and pricing in professional verticals.

London Stock Exchange Group PLC (LSEG.L) · DECREASE · Net Flow +£2,639.35

Analysis: LSEG valuation attractive post recent AI-fear selloff; earnings quality high with recurring data revenues and strong revision trends. Momentum bottoming with analyst upgrades. Resilient balance sheet, robust liquidity. AI thesis strengthened: data infrastructure and MCP server enable AI agents; partnerships with OpenAI, Anthropic, Databricks create new consumption/pricing upside despite workflow automation risks.

Bull Case: AI platforms drive materially higher structured data consumption via LSEG's MCP and feeds, supporting re-rating and 25-30% upside over 6-18 months as per UBS.

Bear Case: Rapid AI automation of trading, compliance, and data workflows displaces legacy exchange/data services faster than new AI-driven demand materializes.

Reason: Reduce from 26% to manage concentration after AI-driven volatility; retained as core AI data/infrastructure play with analyst view of limited displacement risk and attractive entry post-selloff.

Key Risk: AI-native platforms bypassing traditional market infrastructure and data licensing.

The Sage Group plc (SGE.L) · INCREASE · Net Flow -£521.92

Analysis: Sage offers reasonable valuation for growth software with high recurring revenues and improving earnings quality/revision trends via cloud migration and AI features (automation, insights). Momentum constructive; solid balance sheet and liquidity. AI thesis durable: accounting/ERP AI copilots and automation drive adoption and stickiness in SME/mid-market.

Bull Case: AI-powered automation and advisory features accelerate Sage's cloud transition and ARR growth to double-digit rates, expanding margins and multiple over 6-18 months.

Bear Case: Intense competition from AI-native fintech/accounting disruptors or slower SME adoption of paid AI upsells compresses growth and margins.

Reason: Increase allocation to capitalize on AI-driven software automation tailwinds in resilient UK-listed name with strong earnings quality and recurring revenue base.

Key Risk: AI-native competitors or open-source tools eroding Sage's pricing power in core accounting/ERP segments.

AstraZeneca PLC (AZN.L) · INCREASE · Net Flow -£334.10

Analysis: AZN trades at reasonable premium for pipeline quality and earnings growth; strong recent results and upward revisions. Balance sheet solid with investment-grade metrics and good liquidity. AI thesis emerging but supportive: partnerships and internal use of AI for drug discovery, target identification, and clinical optimization enhance R&D productivity and success rates.

Bull Case: AI accelerates pipeline success rates and time-to-market for key assets, driving above-consensus EPS growth and re-rating over 6-18 months while providing defensive growth ballast.

Bear Case: Clinical/regulatory setbacks in key late-stage assets or pricing pressure in major markets outweigh AI-driven R&D efficiency gains.

Reason: Modest increase adds defensive large-cap growth with emerging AI R&D leverage; improves portfolio ballast and risk-adjusted profile versus pure thematic growth names.

Key Risk: Pipeline attrition or reimbursement/pricing headwinds in US/EU eroding expected returns on AI-enhanced R&D spend.

Allianz Technology Trust PLC (ATT.L) · INCREASE · Net Flow -£634.99

Analysis: ATT offers diversified tech exposure at modest discount/premium dynamics with underlying holdings benefiting from AI/semiconductor/infrastructure trends. Earnings/NAV momentum positive via tech rally; liquidity adequate for trust structure. AI thesis strong via portfolio companies in software, chips, and digital infrastructure.

Bull Case: Continued AI capex and tech adoption lifts underlying NAV and closes any discount, delivering 15%+ total returns over 6-18 months with built-in diversification.

Bear Case: Tech sector rotation or valuation compression in AI/semiconductor holdings causes NAV drawdown and persistent discount widening.

Reason: Increase enhances diversified tech/AI exposure via professional management and holdings; complements single-stock data names with broader sector access at attractive structure.

Key Risk: Concentrated tech/AI holdings suffer correlated selloff on valuation concerns or delayed monetization of AI investments.

Experian plc (EXPN.L) · INCREASE · Net Flow -£550.37

Analysis: Experian valuation supported by high-quality recurring data revenues, strong earnings quality, and positive revisions. Momentum solid post any AI-fear dips. Resilient balance sheet and excellent liquidity. AI thesis durable: credit/data analytics and AI models central to fraud, identity, and decisioning; expanding AI-powered offerings drive growth.

Bull Case: AI-enhanced credit, fraud, and identity solutions accelerate new product adoption and pricing power, supporting mid-single digit organic growth with margin upside over 6-18 months.

Bear Case: Data privacy regulations or AI model biases/accuracy issues constrain data usage or trigger fines/reputational damage.

Reason: Increase allocation to data/AI analytics leader with resilient model and clear AI tailwinds; complements RELX/LSEG data exposure while adding consumer/commercial verticals.

Key Risk: Stricter global data privacy/AI governance rules limiting Experian's data advantage or increasing compliance costs.

Global X Robotics & Artificial Intelligence UCITS ETF USD Inc (BOTG.L) · ENTER · Net Flow -£2,597.14

Analysis: BOTG.L provides diversified exposure to global robotics/AI leaders (semiconductors, automation, software) via UCITS structure with reasonable expense. Strong underlying momentum from AI capex; liquidity solid for ETF (avg vol ~8k). Improves portfolio AI purity and geographic diversification vs UK-heavy holdings. Valuation reflects growth but justified by structural demand.

Bull Case: Sustained hyperscaler and enterprise AI/robotics spend drives 20%+ NAV growth in underlying holdings, delivering strong total returns with lower single-stock volatility over 6-18 months.

Bear Case: AI capex slowdown or rotation out of tech/semiconductors causes broad de-rating across ETF holdings and tracking underperformance.

Reason: ADD for pure-play diversified AI/robotics exposure via liquid LSE UCITS ETF; beats retained single names on risk-adjusted basis by reducing concentration and adding global leaders (Nvidia ecosystem etc.) with strong structural tailwinds.

Key Risk: High valuations in underlying AI/semiconductor names lead to sharp correction on any growth disappointment or macro rotation.

Invesco Artificial Intelligence Enablers UCITS ETF Acc (IAIX.L) · ENTER · Net Flow -£2,337.43

Analysis: IAIX.L delivers targeted exposure to AI enablers (chips, infrastructure, software, automation) via UCITS with tech-heavy allocation (~92%). Good liquidity and momentum aligned with AI theme. Enhances risk-adjusted returns through broad participation in AI value chain without single-stock risk. Expense ratio competitive.

Bull Case: AI infrastructure buildout and enterprise adoption propel underlying enabler companies, generating 15-25% returns via NAV appreciation and compounding over 6-18 months.

Bear Case: Supply chain bottlenecks, energy constraints, or delayed ROI on AI investments trigger de-rating across enabler stocks held in the ETF.

Reason: ADD to capture broad AI enablers theme via liquid LSE-listed UCITS ETF; superior risk-adjusted profile vs concentrated single names through diversification across AI infrastructure winners while maintaining high thematic conviction.

Key Risk: Over-concentration in high-valuation AI infrastructure names leads to amplified drawdowns on any capex pause or competitive disruption.

Big Yellow Group PLC (BYG.L) · EXIT · Net Flow +£739.84

Analysis: BYG exhibits limited AI relevance (self-storage operations with modest digital tools); recent negative momentum and unrealized loss. Balance sheet adequate but sector faces cyclical and structural headwinds. Low conviction for AI-focused mandate.

Bull Case: E-commerce and urban storage demand recovery drives occupancy and rental growth, supporting modest total returns.

Bear Case: Economic slowdown, hybrid work reducing storage needs, or e-commerce shifts compress occupancy/pricing and NAV.

Reason: EXIT low-AI-conviction name with weakest momentum and sector fit; reallocates capital to higher risk-adjusted AI thematic opportunities.

Key Risk: Macro-driven demand destruction in self-storage sector leading to prolonged underperformance.

Hikma Pharmaceuticals PLC (HIK.L) · EXIT · Net Flow +£751.22

Analysis: HIK generics-focused with limited AI differentiation or growth premium; flat/negative recent performance and competitive/regulatory pressures. Lower AI thesis durability versus data/software/tech names.

Bull Case: New product launches and geographic expansion stabilize revenues and margins.

Bear Case: Intensifying generic competition, regulatory delays, or pricing erosion in key markets pressure profitability.

Reason: EXIT to remove lower-conviction pharma generics exposure lacking strong AI edge; frees capital for superior risk-adjusted AI growth opportunities.

Key Risk: Generic price erosion and regulatory hurdles compressing margins and growth trajectory.